BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23479321)

  • 1. Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects.
    Toossi Z; Funderburg NT; Sirdeshmuk S; Whalen CC; Nanteza MW; Johnson DF; Mayanja-Kizza H; Hirsch CS
    J Infect Dis; 2013 Jun; 207(12):1841-9. PubMed ID: 23479321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals.
    Abad-Fernández M; Vallejo A; Hernández-Novoa B; Díaz L; Gutiérrez C; Madrid N; Muñoz MA; Moreno S
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):149-53. PubMed ID: 24047967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.
    Ravimohan S; Tamuhla N; Steenhoff AP; Letlhogile R; Makutu DK; Nfanyana K; Rantleru T; Tierney A; Nkakana K; Schwartz AB; Gross R; Macgregor RR; Bellamy SL; Frank I; Weissman D; Bisson GP
    J Infect Dis; 2013 Dec; 208(11):1784-93. PubMed ID: 23908475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of microbial translocation products (LPS, sCD14, IgM Endocab) in HIV-1 infected Indian individuals.
    Negi N; Singh R; Sharma A; Das BK; Vajpayee M
    Microb Pathog; 2017 Oct; 111():331-337. PubMed ID: 28801271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.
    Nanteza MW; Mayanja-Kizza H; Charlebois E; Srikantiah P; Lin R; Mupere E; Mugyenyi P; Boom WH; Mugerwa RD; Havlir DV; Whalen CC
    J Infect Dis; 2011 Sep; 204(6):884-92. PubMed ID: 21849285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.
    Wallet MA; Rodriguez CA; Yin L; Saporta S; Chinratanapisit S; Hou W; Sleasman JW; Goodenow MM
    AIDS; 2010 Jun; 24(9):1281-90. PubMed ID: 20559035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.
    Rajasuriar R; Booth D; Solomon A; Chua K; Spelman T; Gouillou M; Schlub TE; Davenport M; Crowe S; Elliott J; Hoy J; Fairley C; Stewart G; Cameron P; Lewin SR
    J Infect Dis; 2010 Oct; 202(8):1254-64. PubMed ID: 20812848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alcohol use predicts elevation in inflammatory marker soluble CD14 in men living with HIV.
    Monnig MA; Kahler CW; Cioe PA; Tucker L; Monti PM; Mayer KH; Ramratnam B
    AIDS Care; 2016 Nov; 28(11):1434-40. PubMed ID: 27242060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting.
    Pilakka-Kanthikeel S; Kris A; Selvaraj A; Swaminathan S; Pahwa S
    J Acquir Immune Defic Syndr; 2014 May; 66(1):16-24. PubMed ID: 24378729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Use of Proton Pump Inhibitors Is Associated With Increased Microbial Product Translocation, Innate Immune Activation, and Reduced Immunologic Recovery in Patients With Chronic Human Immunodeficiency Virus-1 Infection.
    Serpa JA; Rueda AM; Somasunderam A; Utay NS; Lewis D; Couturier JP; Breaux KG; Rodriguez-Barradas M
    Clin Infect Dis; 2017 Oct; 65(10):1638-1643. PubMed ID: 29020215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS).
    Viladés C; Escoté X; López-Dupla M; Martinez E; Domingo P; Asensi V; Leal M; Peraire J; Inza MI; Arnedo M; Gutiérrez M; Valle-Garay E; Ferrando-Martinez S; Olona M; Alba V; Sirvent JJ; Gatell JM; Vidal F;
    J Antimicrob Chemother; 2014 Jun; 69(6):1653-9. PubMed ID: 24535275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased gut microbial translocation in HIV-infected children persists in virologic responders and virologic failures after antiretroviral therapy.
    Pilakka-Kanthikeel S; Huang S; Fenton T; Borkowsky W; Cunningham CK; Pahwa S
    Pediatr Infect Dis J; 2012 Jun; 31(6):583-91. PubMed ID: 22333700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reconstitution in HIV+ subjects on lopinavir/ritonavir-based HAART according to the severity of pre-therapy CD4+.
    Marchetti G; Merlini E; Sinigaglia E; Iannotti N; Bai F; Savoldi A; Tincati C; Carpani G; Bini T; Arminio Monforte A
    Curr HIV Res; 2012 Oct; 10(7):597-605. PubMed ID: 22716104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in frequencies of circulating Th-17 cells correlates with microbial translocation, immune activation and exhaustion in HIV-1 infected patients with poor CD4 T-cell reconstitution.
    Valiathan R; Asthana D
    Immunobiology; 2016 May; 221(5):670-8. PubMed ID: 26817581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
    Mahan CS; Walusimbi M; Johnson DF; Lancioni C; Charlebois E; Baseke J; Chervenak KA; Mugerwa RD; Havlir DV; Mayanja-Kizza H; Whalen CC; Boom WH;
    PLoS One; 2010 Feb; 5(2):e9138. PubMed ID: 20179751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Activation at Sites of HIV/TB Co-Infection Contributes to the Pathogenesis of HIV-1 Disease.
    Meng Q; Sayin I; Canaday DH; Mayanja-Kizza H; Baseke J; Toossi Z
    PLoS One; 2016; 11(11):e0166954. PubMed ID: 27870882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans.
    Eller MA; Blom KG; Gonzalez VD; Eller LA; Naluyima P; Laeyendecker O; Quinn TC; Kiwanuka N; Serwadda D; Sewankambo NK; Tasseneetrithep B; Wawer MJ; Gray RH; Marovich MA; Michael NL; de Souza MS; Wabwire-Mangen F; Robb ML; Currier JR; Sandberg JK
    PLoS One; 2011 Apr; 6(4):e18779. PubMed ID: 21526194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections.
    Nowroozalizadeh S; Månsson F; da Silva Z; Repits J; Dabo B; Pereira C; Biague A; Albert J; Nielsen J; Aaby P; Fenyö EM; Norrgren H; Holmgren B; Jansson M
    J Infect Dis; 2010 Apr; 201(8):1150-4. PubMed ID: 20199244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3.
    Lancioni CL; Mahan CS; Johnson DF; Walusimbi M; Chervenak KA; Nalukwago S; Charlebois E; Havlir D; Mayanja-Kizza H; Whalen CC; Boom WH
    J Infect Dis; 2011 Apr; 203(7):992-1001. PubMed ID: 21402550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.